List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4742361/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Microencapsulated <i>Bifidobacterium longum</i> subsp. <i>infantis</i> ATCC 15697 Favorably Modulates Gut Microbiota and Reduces Circulating Endotoxins in F344 Rats. BioMed Research International, 2014, 2014, 1-11.	1.9	2,927
2	Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. Cellular and Molecular Life Sciences, 2017, 74, 3769-3787.	5.4	362
3	Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active <i>Lactobacillus reuteri</i> NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. British Journal of Nutrition, 2012, 107, 1505-1513.	2.3	246
4	Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Advanced Drug Delivery Reviews, 2011, 63, 1340-1351.	13.7	226
5	Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. European Journal of Clinical Nutrition, 2012, 66, 1234-1241.	2.9	212
6	Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nature Medicine, 1996, 2, 883-887.	30.7	204
7	Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics: Targets and Therapy, 2011, 5, 71.	3.2	181
8	Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials, 2013, 34, 1270-1280.	11.4	161
9	Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices. Applied Microbiology and Biotechnology, 2010, 88, 401-407.	3.6	158
10	Complements and the Wound Healing Cascade: An Updated Review. Plastic Surgery International, 2013, 2013, 1-7.	0.7	153
11	Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. Expert Opinion on Biological Therapy, 2013, 13, 631-642.	3.1	140
12	Oral Supplementation With Probiotic <i>L. reuteri</i> NCIMB 30242 Increases Mean Circulating 25-Hydroxyvitamin D: A Post Hoc Analysis of a Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2944-2951.	3.6	134
13	Microbial Medicine: Prebiotic and Probiotic Functional Foods to Target Obesity and Metabolic Syndrome. International Journal of Molecular Sciences, 2020, 21, 2890.	4.1	133
14	Effect of Probiotics Lactobacillus and Bifidobacterium on Gut-Derived Lipopolysaccharides and Inflammatory Cytokines: An In Vitro Study Using a Human Colonic Microbiota Model. Journal of Microbiology and Biotechnology, 2013, 23, 518-526.	2.1	129
15	Bone Marrow Stem Cell Derived Paracrine Factors for Regenerative Medicine: Current Perspectives and Therapeutic Potential. Bone Marrow Research, 2011, 2011, 1-14.	1.7	124
16	Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. Journal of Medical Microbiology, 2013, 62, 1107-1123.	1.8	118
17	The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention. Expert Opinion on Biological Therapy, 2014, 14, 467-482.	3.1	116
18	Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization. Nanomaterials, 2016, 6, 116.	4.1	113

#	Article	IF	CITATIONS
19	Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. International Journal of Nanomedicine, 2010, 5, 525.	6.7	112
20	Therapeutic uses of microencapsulated genetically engineered cells. Trends in Molecular Medicine, 1998, 4, 221-227.	2.6	103
21	Cholesterol Assimilation by <i>Lactobacillus</i> Probiotic Bacteria: An <i>In Vitro</i> Investigation. BioMed Research International, 2014, 2014, 1-9.	1.9	103
22	Carbon nanotube lipid drug approach for targeted delivery of a chemotherapy drug in a human breast cancer xenograft animal model. Biomaterials, 2013, 34, 10109-10119.	11.4	91
23	Genipin Cross-Linked Alginate-Chitosan Microcapsules:  Membrane Characterization and Optimization of Cross-Linking Reaction. Biomacromolecules, 2006, 7, 2091-2098.	5.4	89
24	In vitro study of alginate?chitosan microcapsules: an alternative to liver cell transplants for the treatment of liver failure. Biotechnology Letters, 2005, 27, 317-322.	2.2	88
25	Cationic Albumin Nanoparticles for Enhanced Drug Delivery to Treat Breast Cancer: Preparation and <i>In Vitro</i> Assessment. Journal of Drug Delivery, 2012, 2012, 1-8.	2.5	86
26	Reaction of chitosan with genipin and its fluorogenic attributes for potential microcapsule membrane characterization. Journal of Biomedical Materials Research - Part A, 2005, 75A, 917-927.	4.0	83
27	Superior Cell Delivery Features of Poly(ethylene glycol) Incorporated Alginate, Chitosan, and Poly-I-lysine Microcapsules. Molecular Pharmaceutics, 2005, 2, 29-36.	4.6	81
28	Microencapsulated Genetically EngineeredLactobacillus plantarum80 (pCBH1) for Bile Acid Deconjugation and Its Implication in Lowering Cholesterol. Journal of Biomedicine and Biotechnology, 2004, 2004, 61-69.	3.0	76
29	Longevity extension in Drosophila through gut-brain communication. Scientific Reports, 2018, 8, 8362.	3.3	72
30	Procedures for Microencapsulation of Enzymes, Cells and Genetically Engineered Microorganisms. Molecular Biotechnology, 2001, 17, 249-260.	2.4	71
31	The Gut Microbiota and Human Health with an Emphasis on the Use of Microencapsulated Bacterial Cells. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-12.	3.0	71
32	Estimation of the Potential Antitumor Activity of Microencapsulated Lactobacillus acidophilus Yogurt Formulation in the Attenuation of Tumorigenesis in Apc(Min/+) Mice. Digestive Diseases and Sciences, 2009, 54, 264-273.	2.3	68
33	Biotransformation of polyphenols in a dynamic multistage gastrointestinal model. Food Chemistry, 2016, 204, 453-462.	8.2	64
34	Artificial Cell Therapy: New Strategies for the Therapeutic Delivery of Live Bacteria. Journal of Biomedicine and Biotechnology, 2005, 2005, 44-56.	3.0	63
35	The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT/DNAAng1+Vegf nanoparticles. Biomaterials, 2012, 33, 7655-7664.	11.4	63
36	Preparation and in vitro analysis of microencapsulated genetically engineeredE. coli DH5 cells for urea and ammonia removal. Biotechnology and Bioengineering, 1995, 46, 621-626.	3.3	61

#	Article	IF	CITATIONS
37	A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis. International Journal of Nanomedicine, 2011, 6, 485.	6.7	61
38	A novel synbiotic delays Alzheimer's disease onset via combinatorial gut-brain-axis signaling in Drosophila melanogaster. PLoS ONE, 2019, 14, e0214985.	2.5	61
39	Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. International Journal of Nanomedicine, 2013, 8, 2041.	6.7	60
40	Tailoring biomaterial surface properties to modulate host-implant interactions: implication in cardiovascular and bone therapy. Journal of Materials Chemistry B, 2016, 4, 1586-1599.	5.8	59
41	Novel nitric oxide producing probiotic wound healing patch: preparation and in vivo analysis in a New Zealand white rabbit model of ischaemic and infected wounds. International Wound Journal, 2012, 9, 330-343.	2.9	58
42	Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats. Applied Microbiology and Biotechnology, 2014, 98, 115-126.	3.6	57
43	Microencapsulated stem cells for tissue repairing: implications in cell-based myocardial therapy. Regenerative Medicine, 2009, 4, 733-745.	1.7	56
44	Orally Delivered Microencapsulated Live Probiotic Formulation Lowers Serum Lipids in Hypercholesterolemic Hamsters. Journal of Medicinal Food, 2009, 12, 310-319.	1.5	55
45	A novel nitric oxide producing probiotic patch and its antimicrobial efficacy: preparation and in vitro analysis. Applied Microbiology and Biotechnology, 2010, 87, 509-516.	3.6	55
46	Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: A randomized control trial. Regulatory Toxicology and Pharmacology, 2012, 63, 313-320.	2.7	54
47	Probiotic Ferulic Acid Esterase Active Lactobacillus fermentum NCIMB 5221 APA Microcapsules for Oral Delivery: Preparation and in Vitro Characterization. Pharmaceuticals, 2012, 5, 236-248.	3.8	53
48	Functional Assessment of Adipose Stem Cells for Xenotransplantation Using Myocardial Infarction Immunocompetent Models: Comparison with Bone Marrow Stem Cells. Cell Biochemistry and Biophysics, 2013, 67, 263-273.	1.8	53
49	The gut microbiome, probiotics, bile acids axis, and human health. Trends in Microbiology, 2014, 22, 306-308.	7.7	53
50	A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy. Biomaterials, 2011, 32, 8304-8318.	11.4	51
51	Design and validation of an orally administrated active L. fermentum-L. acidophilus probiotic formulation using colorectal cancer Apc Min/+ mouse model. Applied Microbiology and Biotechnology, 2017, 101, 1999-2019.	3.6	50
52	Dual-functionalized graphene oxide for enhanced siRNA delivery to breast cancer cells. Colloids and Surfaces B: Biointerfaces, 2016, 147, 315-325.	5.0	49
53	Probiotics as oral health biotherapeutics . Expert Opinion on Biological Therapy, 2012, 12, 1207-1220.	3.1	48
54	Preparation and characterization of novel polymeric microcapsules for live cell encapsulation and therapy. Cell Biochemistry and Biophysics, 2007, 47, 159-167.	1.8	47

#	Article	IF	CITATIONS
55	Microencapsulation to reduce mechanical loss of microspheres: implications in myocardial cell therapy. European Journal of Cardio-thoracic Surgery, 2011, 39, 241-247.	1.4	47
56	The Microbiome and Alzheimer's Disease: Potential and Limitations of Prebiotic, Synbiotic, and Probiotic Formulations. Frontiers in Bioengineering and Biotechnology, 2020, 8, 537847.	4.1	47
57	Emerging science of the human microbiome. Gut Microbes, 2014, 5, 446-457.	9.8	46
58	Live encapsulated Lactobacillus acidophilus cells in yogurt for therapeutic oral delivery: preparation and in vitro analysis of alginate–chitosan microcapsulesThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products Canadian Journal of Physiology and Pharmacology, 2007, 85, 884-893.	1.4	45
59	Investigation of siRNA-Loaded Polyethylenimine-Coated Human Serum Albumin Nanoparticle Complexes for the Treatment of Breast Cancer. Cell Biochemistry and Biophysics, 2011, 61, 277-287.	1.8	45
60	Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: A randomized, placebo-controlled, double-blind study. Food and Chemical Toxicology, 2012, 50, 2216-2223.	3.6	45
61	Prevention and Treatment of Virulent Bacterial Biofilms with an Enzymatic Nitric Oxide-Releasing Dressing. Antimicrobial Agents and Chemotherapy, 2012, 56, 6095-6103.	3.2	44
62	A novel polyphenolic prebiotic and probiotic formulation have synergistic effects on the gut microbiota influencing <i>Drosophila melanogaster</i> physiology. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 441-455.	2.8	44
63	Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells. Drug Development and Industrial Pharmacy, 2009, 35, 719-726.	2.0	41
64	Microbiome and Human Aging: Probiotic and Prebiotic Potentials in Longevity, Skin Health and Cellular Senescence. Nutrients, 2021, 13, 4550.	4.1	41
65	Microencapsulation for the Therapeutic Delivery of Drugs, Live Mammalian and Bacterial Cells, and Other Biopharmaceutics: Current Status and Future Directions. Journal of Pharmaceutics, 2013, 2013, 1-19.	4.7	40
66	Microencapsulated bile salt hydrolase producing Lactobacillus reuteri for oral targeted delivery in the gastrointestinal tract. Applied Microbiology and Biotechnology, 2008, 81, 225-233.	3.6	39
67	Oral Probiotic Microcapsule Formulation Ameliorates Non-Alcoholic Fatty Liver Disease in Bio F1B Golden Syrian Hamsters. PLoS ONE, 2013, 8, e58394.	2.5	38
68	In vitro and in vivo Uric Acid Lowering by Artificial Cells Containing Microencapsulated Genetically Engineered E. coli DH5 Cells. International Journal of Artificial Organs, 2000, 23, 429-435.	1.4	37
69	Investigation of a New Microcapsule Membrane Combining Alginate, Chitosan, Polyethylene Glycol and Poly-L-Lysine for Cell Transplantation Applications. International Journal of Artificial Organs, 2005, 28, 631-637.	1.4	36
70	Novel probiotic dissolvable carboxymethyl cellulose films as oral health biotherapeutics: <i>in vitro</i> preparation and characterization. Expert Opinion on Drug Delivery, 2013, 10, 1471-1482.	5.0	36
71	A New Carbon Nanotube-Based Breast Cancer Drug Delivery System: Preparation and In Vitro Analysis Using Paclitaxel. Cell Biochemistry and Biophysics, 2015, 71, 1405-1414.	1.8	35
72	Effects of Simulated Human Gastrointestinal Digestion of Two Purple-Fleshed Potato Cultivars on Anthocyanin Composition and Cytotoxicity in Colonic Cancer and Non-Tumorigenic Cells. Nutrients, 2017, 9, 953.	4.1	35

#	Article	IF	CITATIONS
73	Polyethylene glycol and octa-arginine dual-functionalized nanographene oxide: an optimization for efficient nucleic acid delivery. Biomaterials Science, 2018, 6, 1636-1650.	5.4	35
74	Nanomedicine in cardiovascular therapy: recent advancements. Expert Review of Cardiovascular Therapy, 2012, 10, 805-815.	1.5	34
75	Expression of SEAP (secreted alkaline phosphatase) by baculovirus mediated transduction of HEK 293 cells in a hollow fiber bioreactor system. Journal of Biotechnology, 2008, 135, 272-280.	3.8	33
76	Genipin-Cross-Linked Microencapsulated Human Adipose Stem Cells Augment Transplant Retention Resulting in Attenuation of Chronically Infarcted Rat Heart Fibrosis and Cardiac Dysfunction. Cell Transplantation, 2012, 21, 2735-2751.	2.5	33
77	Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization. Scientific Reports, 2013, 3, 2366.	3.3	33
78	Absorption and Metabolism of Phenolics from Digests of Polyphenol-Rich Potato Extracts Using the Caco-2/HepG2 Co-Culture System. Foods, 2018, 7, 8.	4.3	33
79	In-vitroanalysis of APA microcapsules for oral delivery of live bacterial cells. Journal of Microencapsulation, 2005, 22, 539-547.	2.8	32
80	Toward a New Generation of Therapeutics: Artificial Cell Targeted Delivery of Live Cells for Therapy. Applied Biochemistry and Biotechnology, 2006, 128, 001-022.	2.9	32
81	Investigation of Microencapsulated BSH ActiveLactobacillusin the Simulated Human GI Tract. Journal of Biomedicine and Biotechnology, 2007, 2007, 1-9.	3.0	32
82	Superior Cell Delivery Features of Genipin Crosslinked Polymeric Microcapsules: Preparation, In Vitro Characterization and Pro-Angiogenic Applications Using Human Adipose Stem Cells. Molecular Biotechnology, 2011, 48, 116-127.	2.4	31
83	Orally delivered microencapsulated probiotic formulation favorably impacts polyp formation in APC (Min/+) model of intestinal carcinogenesis. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1-11.	2.8	31
84	Artificial cell microcapsule for oral delivery of live bacterial cells for therapy: design, preparation, and in-vitro characterization. Journal of Pharmacy and Pharmaceutical Sciences, 2004, 7, 315-24.	2.1	31
85	Free and Microencapsulated <i>Lactobacillus</i> and Effects of Metabolic Induction on Urea Removal. Artificial Cells, Blood Substitutes, and Biotechnology, 2003, 31, 425-434.	0.9	30
86	Microencapsulated bacterial cells can be used to produce the enzyme feruloyl esterase: preparation and in-vitro analysis. Applied Microbiology and Biotechnology, 2007, 75, 1023-1029.	3.6	30
87	Bioengineered baculoviruses as new class of therapeutics using micro and nanotechnologies: Principles, prospects and challenges. Advanced Drug Delivery Reviews, 2014, 71, 115-130.	13.7	30
88	PAMAM Dendrimer-Baculovirus Nanocomplex for Microencapsulated Adipose Stem Cell-Gene Therapy: <i>In Vitro</i> and <i>in Vivo</i> Functional Assessment. Molecular Pharmaceutics, 2012, 9, 2479-2488.	4.6	29
89	Biotransformation of anthocyanins from two purple-fleshed sweet potato accessions in a dynamic gastrointestinal system. Food Chemistry, 2016, 192, 171-177.	8.2	28
90	Nanoscaffold based stem cell regeneration therapy: recent advancement and future potential. Expert Opinion on Biological Therapy, 2010, 10, 1649-1661.	3.1	27

SATYA PRAKASH

#	Article	IF	CITATIONS
91	Current developments in the tissue engineering of autologous heart valves: moving towards clinical use. Future Cardiology, 2011, 7, 77-97.	1.2	27
92	Investigation of probiotic bacteria as dental caries and periodontal disease biotherapeutics. Beneficial Microbes, 2014, 5, 447-460.	2.4	27
93	Recent Advances in Drug Delivery: Potential and Limitations of Carbon Nanotubes. Recent Patents on Drug Delivery and Formulation, 2007, 1, 214-221.	2.1	26
94	Genipin Cross-Linked Polymeric Alginate-Chitosan Microcapsules for Oral Delivery: In-Vitro Analysis. International Journal of Polymer Science, 2009, 2009, 1-16.	2.7	26
95	Probiotics for the Prevention and Treatment of Allergies, with an Emphasis on Mode of Delivery and Mechanism of Action. Current Pharmaceutical Design, 2014, 20, 1025-1037.	1.9	26
96	Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction. International Journal of Nanomedicine, 2012, 7, 663.	6.7	25
97	Topical application of complement C3 in collagen formulation increases early wound healing. Journal of Dermatological Treatment, 2013, 24, 141-147.	2.2	24
98	Preparation and <i>in vitro</i> analysis of microencapsulated live <i>Lactobacillus fermentum</i> 11976 for augmentation of feruloyl esterase in the gastrointestinal tract. Biotechnology and Applied Biochemistry, 2008, 50, 1-9.	3.1	23
99	Investigation on PEG Integrated Alginate–Chitosan Microcapsules for Myocardial Therapy Using Marrow Stem Cells Genetically Modified by Recombinant Baculovirus. Cardiovascular Engineering and Technology, 2010, 1, 154-164.	1.6	23
100	Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer. International Journal of Biomaterials, 2013, 2013, 1-13.	2.4	23
101	Suppression of Tumorigenesis: Modulation of Inflammatory Cytokines by Oral Administration of Microencapsulated Probiotic Yogurt Formulation. International Journal of Inflammation, 2010, 2010, 1-10.	1.5	22
102	Diet-induced metabolic hamster model of nonalcoholic fatty liver disease. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2011, 4, 195.	2.4	22
103	Transit Time Affects the Community Stability of <i>Lactobacillus</i> and <i>Bifidobacterium</i> Species in an <i>In Vitro</i> Model of Human Colonic Microbiotia. Artificial Cells, Blood Substitutes, and Biotechnology, 2011, 39, 351-356.	0.9	22
104	Ferulic Acid Produced by Lactobacillus fermentum Influences Developmental Growth Through a dTOR-Mediated Mechanism. Molecular Biotechnology, 2019, 61, 1-11.	2.4	21
105	Superior Therapeutic Potential of Young Bone Marrow Mesenchymal Stem Cells by Direct Intramyocardial Delivery in Aged Recipients with Acute Myocardial Infarction: In Vitro and In Vivo Investigation. Journal of Tissue Engineering, 2011, 2011, 741213.	5.5	20
106	Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles. Journal of Pharmaceutics, 2013, 2013, 1-10.	4.7	20
107	A polyphenol-rich prebiotic in combination with a novel probiotic formulation alleviates markers of obesity and diabetes in Drosophila. Journal of Functional Foods, 2018, 48, 374-386.	3.4	20

108 Carbon Nanotubes for Use in Medicine: Potentials and Limitations. , 0, , .

#	Article	IF	CITATIONS
109	Microcapsule carbon nanotube devices for therapeutic applications. Nanotechnology, 2009, 20, 025612.	2.6	18
110	Recombinant Baculovirus as a Highly Potent Vector for Gene Therapy of Human Colorectal Carcinoma: Molecular Cloning, Expression, and In Vitro Characterization. Molecular Biotechnology, 2010, 45, 129-139.	2.4	18
111	Novel microencapsulated probiotic blend for use in metabolic syndrome: design and <i>in-vivo</i> analysis. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 116-124.	2.8	18
112	Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2316-2324.	0.8	17
113	Lactobacillus fermentum NCIMB 5221 and NCIMB 2797 as cholesterol-lowering probiotic biotherapeutics: in vitro analysis. Beneficial Microbes, 2015, 6, 861-869.	2.4	17
114	Novel Milrinone Nanoformulation for Use in Cardiovascular Diseases: Preparation and <i>in Vitro</i> Characterization. Molecular Pharmaceutics, 2018, 15, 2489-2502.	4.6	17
115	Artificial Cells for Bioencapsulation of Cells and Genetically Engineered E. coli: For Cell Therapy, Gene Therapy, and Removal of Urea and Ammonia. , 1997, 63, 343-358.		16
116	Growth and Survival of Renal Failure Rats that Received Oral Microencapsulated Genetically EngineeredE. Coli Dh5Cells for Urea Removal. Artificial Cells, Blood Substitutes, and Biotechnology, 1998, 26, 35-51.	0.9	16
117	Artificial Cell Microcapsules Containing Genetically Engineered E. Coli dhs Cells for In-Vitro Lowering of Plasma Potassium, Phosphate, Magnesium, Sodium, Chloride, Uric Acid, Cholesterol, And Creatinine : A Preliminary Report. Artificial Cells, Blood Substitutes, and Biotechnology, 1999, 27, 475-481.	0.9	16
118	<i>In vitro</i> cytotoxicity of functionalized single walled carbon nanotubes for targeted gene delivery applications. Nanotoxicology, 2008, 2, 184-188.	3.0	16
119	Artificial Cells Microencapsulated Genetically Engineered <i>E. Coli DH 5</i> Cells for the Lowering of Plasma Creatinine In-Vitro and In-Vivo. Artificial Cells, Blood Substitutes, and Biotechnology, 2000, 28, 397-408.	0.9	15
120	Cellular cardiomyoplasty: current state of the field. Regenerative Medicine, 2012, 7, 571-582.	1.7	15
121	Recent advancements in tissue engineering for stem cell-based cardiac therapies. Therapeutic Delivery, 2013, 4, 503-516.	2.2	15
122	Small interfering ribonucleic acid design strategies for effective targeting and gene silencing. Expert Opinion on Drug Discovery, 2011, 6, 269-289.	5.0	14
123	Letter to the editor regarding the report of Duboc <i>et al</i> : connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease. Gut, 2013, 62, 654-655.	12.1	14
124	Microencapsulated genetically engineered E. coli DH5 cells for plasma urea and ammonia removal based on: 1. Column bioreactor and 2. Oral administration in uremic rats. Artificial Cells, Blood Substitutes, and Biotechnology, 1996, 24, 201-218.	0.9	12
125	Intranasal Delivery of Chitosan–siRNA Nanoparticle Formulation to the Brain. Methods in Molecular Biology, 2014, 1141, 233-247.	0.9	12
126	Expression and Production of Human Interleukin-7 in Insect Cells Using Baculovirus Expression Vector System (BEVS). Applied Biochemistry and Biotechnology, 2008, 151, 93-103.	2.9	11

#	Article	IF	CITATIONS
127	In vitro and in vivo uric acid lowering by artificial cells containing microencapsulated genetically engineered E. coli DH5 cells. International Journal of Artificial Organs, 2000, 23, 429-35.	1.4	11
128	Genetically EngineeredE. COLICells ContainingK. AEROGENESGene, Microencapsulated in Artificial Cells for Urea and Ammonia Removal. Biomaterials, Artificial Cells, and Immobilization Biotechnology: Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology, 1993, 21, 629-636.	0.2	10
129	Growth Kinetics of Genetically Engineered E. Colidh5 Cells in Artificial Cell Apa Membrane Microcapsules: Preliminary Report. Artificial Cells, Blood Substitutes, and Biotechnology, 1999, 27, 291-301.	0.9	10
130	A New Method for Targeted Drug Delivery Using Polymeric Microcapsules: Implications for Treatment of Crohn's Disease. Cell Biochemistry and Biophysics, 2005, 43, 077-086.	1.8	10
131	Live bacterial cells as orally delivered therapeutics. Expert Opinion on Biological Therapy, 2005, 5, 1281-1301.	3.1	10
132	Investigation of Genipin Cross-Linked Microcapsule for Oral Delivery of Live Bacterial Cells and Other Biotherapeutics: Preparation and In Vitro Analysis in Simulated Human Gastrointestinal Model. International Journal of Polymer Science, 2010, 2010, 1-10.	2.7	10
133	Improvement of gastrointestinal health status in subjects consuming <i>Lactobacillus reuteri</i> NCIMB 30242 capsules: a <i>post-hoc</i> analysis of a randomized controlled trial. Expert Opinion on Biological Therapy, 2013, 13, 1643-1651.	3.1	10
134	Complements C3 and C5 Individually and in Combination Increase Early Wound Strength in a Rat Model of Experimental Wound Healing. Plastic Surgery International, 2013, 2013, 1-5.	0.7	10
135	Investigation of Antiangiogenic Tumor Therapy Potential of Microencapsulated HEK293 VEGF ₁₆₅ b Producing Cells. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	9
136	Design of a novel gut bacterial adhesion model for probiotic applications. Artificial Cells, Nanomedicine and Biotechnology, 2013, 41, 116-124.	2.8	9
137	A New Method for Microcapsule Characterization: Use of Fluorogenic Genipin to Characterize Polymeric Microcapsule Membranes. Applied Biochemistry and Biotechnology, 2006, 134, 207-222.	2.9	8
138	Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells. Biologics: Targets and Therapy, 2008, 2, 355.	3.2	8
139	Nonviral Production of Human Interleukin-7 in Spodoptera Frugiperda Insect Cells as a Soluble Recombinant Protein. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-8.	3.0	8
140	Nano- and Biotechnological Approaches in Current and Future Generation of Cardiovascular Stents. Current Nanoscience, 2010, 6, 469-478.	1.2	8
141	Safety of transtympanic application of probiotics in a chinchilla animal model. Journal of Otolaryngology - Head and Neck Surgery, 2017, 46, 63.	1.9	8
142	Baculoviruses in Gene Therapy and Personalized Medicine. Biologics: Targets and Therapy, 2021, Volume 15, 115-132.	3.2	8
143	Impact of Orally Administered Microcapsules on Gastrointestinal Microbial Flora: In-Vitro Investigation Using Computer Controlled Dynamic Human Gastrointestinal Model. Artificial Cells, Blood Substitutes, and Biotechnology, 2 <u>0</u> 07, 35, 359-375.	0.9	7
144	Baculovirus reveals a new pH-dependent direct cell-fusion pathway for cell entry and transgene delivery. Future Virology, 2010, 5, 533-537.	1.8	7

#	Article	IF	CITATIONS
145	Albumin Nanoparticle Formulation for Heart-Targeted Drug Delivery: In Vivo Assessment of Congestive Heart Failure. Pharmaceuticals, 2021, 14, 697.	3.8	7
146	Enrichment ofBifidobacterium longumsubsp.infantisATCC 15697 within the human gut microbiota using alginate-poly-l-lysine-alginate microencapsulation oral delivery system: anin vitroanalysis using a computer-controlled dynamic human gastrointestinal model. Journal of Microencapsulation, 2014, 31, 230-238.	2.8	6
147	Synthesis and characterization of peptide conjugated human serum albumin nanoparticles for targeted cardiac uptake and drug delivery. PLoS ONE, 2021, 16, e0254305.	2.5	6
148	Microencapsulated Engineered Lactococcus lactis Cells for Heterologous Protein Delivery: Preparation and In Vitro Analysis. Applied Biochemistry and Biotechnology, 2007, 142, 71-80.	2.9	5
149	BacMam Virus Transduced Cardiomyoblasts Can Be Used for Myocardial Transplantation Using AP-PEG-A Microcapsules: Molecular Cloning, Preparation, and <i>In Vitro</i> Analysis. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-12.	3.0	4
150	Polymeric Microspheres Containing Human Vocal Fold Fibroblasts for Vocal Fold Regeneration. Laryngoscope, 2020, 131, 1828-1834.	2.0	4
151	Route of Delivery, Cell Retention, and Efficiency of Polymeric Microcapsules in Cellular Cardiomyoplasty. Methods in Molecular Biology, 2013, 1036, 121-135.	0.9	4
152	Potentials and limitations of microorganisms as renal failure biotherapeutics. Biologics: Targets and Therapy, 2009, 3, 233-43.	3.2	4
153	Microencapsulated Multifunctionalized Graphene Oxide Equipped with Chloroquine for Efficient and Sustained siRNA Delivery. BioMed Research International, 2022, 2022, 1-16.	1.9	4
154	Live immobilised cells as new therapeutics. Journal of Drug Delivery Science and Technology, 2008, 18, 3-14.	3.0	3
155	Microbial Biotransformation of a Polyphenol-Rich Potato Extract Affects Antioxidant Capacity in a Simulated Gastrointestinal Model. Antioxidants, 2018, 7, 43.	5.1	2
156	Inflammatory bowel diseases: current treatment strategies and potential for drug delivery using artificial cell microcapsules. , 2007, , 454-468.		1
157	Microencapsulated <i>Saccharomyces cerevisiae</i> Column Bioreactor for Potential Use in Renal Failure Uremia. Artificial Cells, Blood Substitutes, and Biotechnology, 2012, 40, 103-112.	0.9	1
158	Angiogenic Nanodelivery Systems for Myocardial Therapy. Methods in Molecular Biology, 2013, 1036, 137-149.	0.9	1
159	Effect of artificial cell miniaturization on urea degradation by immobilized <i>E. coli</i> DH5α (pKAU17). Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 766-775.	2.8	1
160	Artificial cells containing genetically engineered E. coli DH5 cells for urea and ammonia removal in kidney and liver failure. , 0, , .		0
161	Introduction to artificial cells: concept, history, design, current status and future. , 2007, , 3-41.		0
162	Microencapsulated Mammalian Cells for Simultaneous Production of VEGF165b and IFNα. Artificial Cells, Blood Substitutes, and Biotechnology, 2012, 40, 1-6.	0.9	0

#	Article	IF	CITATIONS
163	Nanomaterials and Cardiovascular Toxicity. , 2015, , 547-570.		0
164	Artificial cell microcapsules containing live bacterial cells and activated charcoal for managing renal failure creatinine: preparation and <i>in-vitro</i> analysis. The EuroBiotech Journal, 2019, 3, 190-196.	1.0	0